Coriolis Pharma expands facilities for ATMP development

The expansion close to company's Martinsried headquarters includes a lyophilisation development centre for advanced therapy medicinal products

Formulation research and development specialist Coriolis Pharma has announced that it is expanding its advanced therapy medicinal products (ATMPs) development facilities.

The company says the expansion at an existing building near its headquarters in Martinsried, Germany -- which began in March this year -- will increase total floor space to 7,800 m2 and will enable its new biosafety level S2 (BSL-2) labs to provide formulation development of ATMPs, cell culture activities, particle characterization and identification, analytical ultracentrifugation and, a lyophilisation development center for ATMPs.

Back in 2018, Coriolis Pharma started strengthening its ATMP capabilities in anticipation of expected growth in the sector.

Although ATMPs are experiencing significant growth, ATMP formulations, however, are far from advanced, largely due to their short shelf life (hours to days) or their requirement for ultracold storage conditions.

To further support the laboratory expansion Coriolis Pharma also expanded its scientific advisory board with Prof. Ernst Wagner from the Ludwig-Maximilians-Universität (LMU) Munich and Prof. Gideon Kersten from Leiden University.